Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials.

@article{DAmico2012SurrogateEF,
  title={Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials.},
  author={Anthony V. D'Amico and Ming-Hui Chen and Mario Augusto Ferrari de Castro and Marian J Loffredo and David S. Lamb and Allison Steigler and Philip W. Kantoff and James Denham},
  journal={The Lancet. Oncology},
  year={2012},
  volume={13 2},
  pages={189-95}
}
BACKGROUND Androgen suppression therapy and radiotherapy are used to treat locally advanced prostate cancer. 3 years of androgen suppression confers a small survival benefit compared with 6 months of therapy in this setting, but is associated with more toxic effects. Early identification of men in whom radiotherapy and 6 months of androgen suppression is insufficient for cure is important. Thus, we assessed whether prostate-specific antigen (PSA) values can act as an early surrogate for… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Surrogate endpoints in early prostate cancer research

Translational andrology and urology • 2018
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…